Susquehanna International Group
IMRX icon

Susquehanna International Group’s Immuneering IMRX Stock Holding History

Susquehanna International Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$734K Buy
139,300
+73,700
+112% +$378K ﹤0.01% 8696
2025
Q4 		$432K Buy
+65,600
New +$421K ﹤0.01% 9140

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group's IMRX Position: Q1 2026 in Review

Susquehanna International Group reduced its Immuneering (IMRX) stake by 1.8% in Q1 2026, selling an estimated $10.1K and leaving 105,507 shares worth $556K. The position accounts for ﹤0.01% of the portfolio, ranked #9383.

Susquehanna International Group first reported a position in IMRX in Q4 2022 and has held it in 6 quarters since. The position peaked at $707K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Susquehanna International Group held 105,507 shares of Immuneering worth $556K as of Q1 2026.
  • Susquehanna International Group sold 1,965 Immuneering shares in Q1 2026, an estimated $10.1K.
  • Immuneering made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9383 holding.
  • Susquehanna International Group first reported a position in Immuneering in Q4 2022 and has held it in 6 quarters since.
  • Susquehanna International Group's Immuneering position peaked at $707K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.